An adaptive design for Phase II cancer clinical trials.

Dose escalation design for Phase I cancer clinical trials (CINJ research grant application submitted).

Estimation of area of under the curves in pharmacokinetics when using destructive sampling measurements and its application on determining the effect of hepatic enzyme induction and sublethal hepatic Injury on the tissue and plasma exposure to doxorubicin and metabolites in the rabbits (UMDNJ-RWJMS research grant application submitted).

Supporting all CINJ investigator-initiated phases I/II/III clinical trials and population studies under the NCI- CCSG grant for the Biostatistics Core.

Partial imputation approaches for analyzing clinical data with dependent dropouts.